Literature DB >> 28960490

Safety of secukinumab in hepatitis B virus.

S L Bevans1, T T Mayo1, B E Elewski1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28960490     DOI: 10.1111/jdv.14608

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  5 in total

1.  Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.

Authors:  Matteo Megna; Cataldo Patruno; Maria Rita Bongiorno; Alessio Gambardella; Claudio Guarneri; Paolo Romita; Annunziata Raimondo; Francesco Loconsole; Gabriella Fabbrocini
Journal:  Clin Drug Investig       Date:  2022-05-28       Impact factor: 3.580

2.  An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis.

Authors:  Yuta Koike; Yumi Fujiki; Maho Higuchi; Reika Fukuchi; Sayaka Kuwatsuka; Hiroyuki Murota
Journal:  JAAD Case Rep       Date:  2019-01-25

Review 3.  Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.

Authors:  Alfonso Motolese; Manuela Ceccarelli; Laura Macca; Federica Li Pomi; Ylenia Ingrasciotta; Giuseppe Nunnari; Claudio Guarneri
Journal:  Biomedicines       Date:  2022-01-21

4.  Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption.

Authors:  Anna Campanati; Elisa Molinelli; Valerio Brisigotti; Donatella Brancorsini; Ivan Bobyr; Federico Diotallevi; Giulia Radi; Annamaria Offidani
Journal:  Case Rep Dermatol       Date:  2019-09-23

Review 5.  Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.

Authors:  Shintaro Akiyama; Thomas G Cotter; Atsushi Sakuraba
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.